Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
BMC Immunology|March 31, 2017
Broad induction of immunoregulatory mechanisms after a short course of anti-IL-7Rα antibodies in NOD miceCristina Vazquez-Mateo, Justin Collins, Michelle Fleury, et al.
European Journal of Drug Metabolism and Pharmacokinetics|July 30, 2021
Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical DataIrina Kareva, Anup Zutshi, Cristina Vazquez Mateo, et al.
Cytokine|November 28, 2021
Partial STAT5 signaling is sufficient for CD4+ T cell priming but not memory formationMichelle Fleury, Cristina Vazquez-Mateo, Jaileene Hernandez-Escalante, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 19, 2023
Population pharmacokinetics of atacicept in systemic lupus erythematosus: An analysis of three clinical trialsMaria Pitsiu, Özkan Yalkinoglu, Colm Farrell, et al.
Plos One|March 26, 2019
Combining anti-IL-7Rα antibodies with autoantigen-specific immunotherapy enhances non-specific cytokine production but fails to prevent Type 1 DiabetesCristina Vazquez-Mateo, Justin Collins, Sarah J Goldberg, et al.
Clinical Pharmacology and Therapeutics|April 7, 2022
Applying Modeling and Simulations for Rational Dose Selection of Novel Toll-Like Receptor 7/8 Inhibitor Enpatoran for Indications of High Medical NeedLena Klopp-Schulze, Jamie V Shaw, Jennifer Q Dong, et al.
Rheumatology (Oxford, England)|June 13, 2018
Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung diseaseDinesh Khanna, Donald P Tashkin, Christopher P Denton, et al.
The Journal of Rheumatology|October 2, 2020
STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis-associated Interstitial Lung DiseaseDinesh Khanna, Donald P Tashkin, Athol U Wells, et al.
Rheumatology (Oxford, England)|February 29, 2020
Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II studyEric F Morand, David A Isenberg, Daniel J Wallace, et al.
CPT: Pharmacometrics & Systems Pharmacology|December 5, 2023
Model-based meta-analysis using latent variable modeling to set benchmarks for new treatments of systemic lupus erythematosusKosalaram Goteti, Ramon Garcia, William R Gillespie, et al.
Pageof 2